Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline

Women’s Values and Preferences Regarding Osteoporosis Treatments: A Systematic Review

(2019) Patricia Barrionuevo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates

(2018) Anne M. Horne et al.   CALCIFIED TISSUE INTERNATIONAL

Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression

(2018) Douglas C Bauer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study

(2018) Annette L Adams et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

(2018) Piet Geusens et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Proceedings of the 2017 Santa Fe Bone Symposium: Insights and Emerging Concepts in the Management of Osteoporosis

(2018) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL DENSITOMETRY

ACTIVExtend: 24 Months of Alendronate after 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

(2018) Henry G Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

(2018) David L Kendler et al.   LANCET

Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density

(2018) K. E. Naylor et al.   OSTEOPOROSIS INTERNATIONAL

Effects of vitamin D supplementation on musculoskeletal health: a systematic review, meta-analysis, and trial sequential analysis

(2018) Mark J Bolland et al.   Lancet Diabetes & Endocrinology

Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults

(2017) Jia-Guo Zhao et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

(2017) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Evaluating Atypical Features of Femur Fractures: How Change in Radiological Criteria Influenced Incidence and Demography of Atypical Femur Fractures in a Community Setting

(2017) Erin S LeBlanc et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Worldwide Fracture Prediction

(2017) Ghada El-Hajj Fuleihan et al.   JOURNAL OF CLINICAL DENSITOMETRY

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

(2017) Felicia Cosman et al.   MAYO CLINIC PROCEEDINGS

Observations following discontinuation of long-term denosumab therapy

(2017) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates

(2017) A. Diez-Perez et al.   OSTEOPOROSIS INTERNATIONAL

Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability

(2017) P. Szulc et al.   OSTEOPOROSIS INTERNATIONAL

Imminent fracture risk

(2017) C. Roux et al.   OSTEOPOROSIS INTERNATIONAL

Hip fracture trends in the United States, 2002 to 2015

(2017) E. Michael Lewiecki et al.   OSTEOPOROSIS INTERNATIONAL

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

(2017) Emily Durden et al.   Archives of Osteoporosis

UK clinical guideline for the prevention and treatment of osteoporosis

(2017) J. Compston et al.   Archives of Osteoporosis

THU0461 Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: A Series of 8 Women with 35 Spontaneous Vertebral Fractures

(2016) B. Aubry Rozier et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

(2016) Paul D. Miller et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Crisis in the Treatment of Osteoporosis

(2016) Sundeep Khosla et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research

(2016) Robert A Adler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Impact of the U.S. Food and Drug Administration's Safety-Related Announcements on the Use of Bisphosphonates After Hip Fracture

(2016) Seoyoung C Kim et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis

(2016) Steven R Cummings et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Postmenopausal Osteoporosis

(2016) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imminent risk of fracture after fracture

(2016) H. Johansson et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting

(2016) Andrew Liem Hieu Huynh et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Monthly High-Dose Vitamin D Treatment for the Prevention of Functional Decline

(2016) Heike A. Bischoff-Ferrari et al.   JAMA Internal Medicine

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis

(2016) Koji Ishikawa et al.   Therapeutics and Clinical Risk Management

Risk of atypical femoral fracture during and after bisphosphonate use

(2015) Jörg Schilcher et al.   Acta Orthopaedica

Hypocalcemia Post Denosumab in Patients with Chronic Kidney Disease Stage 4-5

(2015) Vatsa Dave et al.   AMERICAN JOURNAL OF NEPHROLOGY

Associations between calcium and vitamin D supplement use as well as their serum concentrations and subclinical cardiovascular disease phenotypes

(2015) Inke Thiele et al.   ATHEROSCLEROSIS

Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline

(2015) Cynthia A. Stuenkel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis

(2015) Khaled Mohammed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Guideline panels should not GRADE good practice statements

(2015) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update and CTX

(2015) Harry C. Schwartz   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

(2015) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics

(2015) A. W. Popp et al.   OSTEOPOROSIS INTERNATIONAL

Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study

(2015) K. E. Naylor et al.   OSTEOPOROSIS INTERNATIONAL

The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil

(2015) Luiz Francisco Baccaro et al.   Clinical Interventions in Aging

Incidence of hip fracture in Brazil and the development of a FRAX model

(2015) C. A. F. Zerbini et al.   Archives of Osteoporosis

Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis

(2015) Dae Hyun Kim et al.   PLoS One

Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures

(2014) Carolyn J. Crandall et al.   ANNALS OF INTERNAL MEDICINE

Salmon Calcitonin Use and Associated Cancer Risk

(2014) Robert A. Overman et al.   ANNALS OF PHARMACOTHERAPY

Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus

(2014) Aliya A Khan et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial

(2014) JoAnn V. Pinkerton et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Calcitonin Nasal Spray and Increased Cancer Risk: A Population-Based Nested Case-Control Study

(2014) Li-Min Sun et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis

(2014) John W. Hellstein et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Burden of proximal humerus fractures in the French National Hospital Database

(2014) M. Maravic et al.   Orthopaedics & Traumatology-Surgery & Research

Clinician’s Guide to Prevention and Treatment of Osteoporosis

(2014) F. Cosman et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study

(2014) M. A. Paggiosi et al.   OSTEOPOROSIS INTERNATIONAL

Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women’s Health Initiative Randomized Trials

(2013) JoAnn E. Manson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: A systematic review and meta-analysis

(2013) Lydia Gedmintas et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

(2013) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Treat-to-target for Osteoporosis: Is Now the Time?

(2013) E. Michael Lewiecki et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

(2013) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

(2013) Jack Cuzick et al.   LANCET

Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study

(2013) David L. Kendler et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

The Auckland calcium study: 5-year post-trial follow-up

(2013) L. T. Radford et al.   OSTEOPOROSIS INTERNATIONAL

Bone strength and surrogate markers: The first, second, and third fiddle

(2012) Paul D Miller   JOURNAL OF BONE AND MINERAL RESEARCH

A single-dose study of denosumab in patients with various degrees of renal impairment

(2012) Geoffrey A Block et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Incidence and demography of femur fractures with and without atypical features

(2012) Adrianne C Feldstein et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Incidence of atypical nontraumatic diaphyseal fractures of the femur

(2012) Richard M Dell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial

(2012) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Continuing Bisphosphonate Treatment for Osteoporosis — For Whom and for How Long?

(2012) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice

(2012) I. Baxter et al.   OSTEOPOROSIS INTERNATIONAL

Treatment failure in osteoporosis

(2012) A. Diez-Perez et al.   OSTEOPOROSIS INTERNATIONAL

Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience

(2011) A. M. Vandone et al.   ANNALS OF ONCOLOGY

Impact of Medication Adherence on Health Care Utilization and Productivity: Self-Reported Data From a Cohort of Postmenopausal Women on Osteoporosis Therapy

(2011) Sally W. Wade et al.   CLINICAL THERAPEUTICS

Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women

(2011) Laura Y. Park-Wyllie   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effects of denosumab on fracture and bone mineral density by level of kidney function

(2011) Sophie A Jamal et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence

(2011) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women

(2011) Stephen Gehlbach et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Estimation of the lifetime risk of hip fracture for women and men in Canada

(2011) R. B. Hopkins et al.   OSTEOPOROSIS INTERNATIONAL

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

(2011) N. B. Watts et al.   OSTEOPOROSIS INTERNATIONAL

Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study

(2011) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

(2011) Tim Van den Wyngaert et al.   SUPPORTIVE CARE IN CANCER

Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women

(2010) Kerrie M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

(2010) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement

(2010) Richard J. Santen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis

(2010) Bo Abrahamsen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know

(2010) A. Catharine Ross et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

(2010) J.-J. Body et al.   OSTEOPOROSIS INTERNATIONAL

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

(2010) S. Vasikaran et al.   OSTEOPOROSIS INTERNATIONAL

Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture

(2010) K. M. B. Huntjens et al.   OSTEOPOROSIS INTERNATIONAL

Gastric and Esophagus Events Before and During Treatment of Osteoporosis

(2009) Peter Vestergaard et al.   CALCIFIED TISSUE INTERNATIONAL

Proximal Humeral Fracture as a Risk Factor for Subsequent Hip Fractures

(2009) Jeremiah Clinton et al.   JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME

Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis

(2009) Nelson B Watts et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure

(2009) Joan C. Lo et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

(2009) Peter Kenemans et al.   LANCET ONCOLOGY

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

(2008) M. A. Dimopoulos et al.   ANNALS OF ONCOLOGY

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans

(2008) Tony M Keaveny et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial*

(2008) Stuart L Silverman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)*

(2008) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Effects of Tibolone in Older Postmenopausal Women

(2008) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate

(2008) Brett A. Lenart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal